Firefly Neuroscience Inc (AIFF) Stock AnalysisAIFFStock AnalysisFirefly Neuroscience Inc

Firefly Neuroscience, Inc. is an artificial intelligence (AI) company advancing precision neuroscience. The Company's BNA Platform and Evoke System are Class II medical devices, which were cleared by FDA for commercialization. The Company's FDA-510(k) cleared Evoke System, commercially deployed as the Evoke System, is in active use over 85 clinical sites in the United States. The Company has developed Firefly Platform, a vertically integrated hardware, software, and data infrastructure that captures standardized electroencephalographic (EEG) and event-related potential (ERP) assessments at the point of care, analyzes that data through its proprietary analytics engine, and delivers structured, clinician-ready reports back to the provider, all within a single seamless workflow. Its proprietary analytics engine analyzes raw EEG and ERP signals across captured dimensions and compares each patient’s electrophysiological profile to a reference dataset. It operates in the Technology sector.

Firefly Neuroscience Inc is a good buy right now due to its recent partnership with the Department of Defense, which could significantly enhance its revenue potential. The stock has shown a year-to-date change of +21.27%, indicating positive momentum. However, the company is still facing challenges with a net income loss of -2,198,000 USD in Q2 2026. The current price is 1.08, and with a projected trajectory suggesting a potential +103% increase, this presents a compelling opportunity for long-term investors.